Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to -$67000.0.

  • Rocket Pharmaceuticals' Cash from Financing Activities fell 13806.82% to -$67000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $183.0 million, marking a year-over-year increase of 547747.64%. This contributed to the annual value of $185.7 million for FY2024, which is 1087.42% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Cash from Financing Activities of -$67000.0 as of Q3 2025, which was down 13806.82% from $215000.0 recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Cash from Financing Activities ranged from a high of $189.5 million in Q3 2023 and a low of -$67000.0 during Q3 2025
  • Its 5-year average for Cash from Financing Activities is $32.6 million, with a median of $1.4 million in 2024.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Cash from Financing Activities surged by 4666445.01% in 2024, and later crashed by 13806.82% in 2025.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Cash from Financing Activities stood at $1.1 million in 2021, then surged by 9445.77% to $108.4 million in 2022, then crashed by 99.64% to $391000.0 in 2023, then surged by 46664.45% to $182.8 million in 2024, then plummeted by 100.04% to -$67000.0 in 2025.
  • Its Cash from Financing Activities stands at -$67000.0 for Q3 2025, versus $215000.0 for Q2 2025 and $182.8 million for Q4 2024.